Impact of pharmacist interventions on drug-related problems and laboratory markers in outpatients with human immunodeficiency virus infection

Molino, Caroline de Godoi Rezende Costa; Carnevale, Renata Cavalcanti; Rodrigues, Antônio Flavio Aires; Visacri, Marília Berlofa; Moriel, Patrícia; Mazzola, Priscila Gava

doi:10.2147/tcrm.s61821

Cited by 16 publications

(20 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…13 Molino et al also had similar findings in a prospective controlled study, reporting that pharmacist interventions were generally accepted by physicians, leading to a change in medication therapy. 15 Furthermore, the interventions were well accepted by patients as well, although the compliance with the interventions was not measured. 14 These findings suggest that the importance of the pharmacist in healthcare is well recognized by physicians, as is the significance of the pharmaceutical practices in clinical settings.…”

Section: Discussionmentioning

confidence: 99%

“…These findings differ somewhat from those found in a previous study in which DRPs commonly involved adverse drug reactions (30.4%) and patient non-compliance (30.4%), followed by untreated indications (10.7%), drug interactions and supratherapeutic/sub-therapeutic doses (7.1% each), improper drug selection (5.4%), and drug use without indication (1.8%). 15 Another study was conducted at a private hospital in Riyadh City, Saudi Arabia to investigate the intervention of clinical pharmacist's services at critical care units. This study reported that the most common DRPs were inappropriate dose (20.05%), followed by drug duplication (11.29%), and unsuitable route (6.87%) and DDIs (1.96%).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

<p>Drug-Related Problems and Pharmacist Intervention at a General Hospital in the Jazan Region, Saudi Arabia</p>

Babelghaith

Wajid

Alrabiah

et al. 2020

RMHP

View full text Add to dashboard Cite

Patients and Methods: This retrospective study was conducted among inpatients at Ministry of Health hospital in Jazan, a region in southwestern Saudi Arabia. We collected data for a 2-year period (from 2016 to 2017). For any detected DRP of the ordered medications for dispensing, the inpatient pharmacist is sending report for that particular DRP with recommendation to the medical team which in turn might accept or reject such recommendation. Serious drug-drug interactions, as part of DRP, were assessed by utilizing three different online DDI checkers, including Lexi-Comp, Medscape, and Drugs.com. Results: The most common type of DRP was serious drug-drug interactions (49%). Over the study period, most incidences of DRPs were decreased. Of the DRPs in 2016 and 2017, antibiotics were the most commonly involved (51% and 69.5%) of cases, respectively, followed by proton pump inhibitors (25.3% and 14.1%) and statins (12.9% and 9.4%). Interestingly, of the 241 interventions for DRPs in 2016, 199 (82.5%) were accepted, resulting in a change in drug therapy (p=0.006). In 2017, 90 (70.3%) interventions out of 128 were accepted by the physician and the drug therapy changed (p=0.029). Conclusion: Pharmacist interventions appear to decrease the incidence of DRPs, which emphasize the importance of an optimal pharmaceutical care plan for clinical care settings.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

<p>Drug-Related Problems and Pharmacist Intervention at a General Hospital in the Jazan Region, Saudi Arabia</p>

Babelghaith

Wajid

Alrabiah

et al. 2020

RMHP

View full text Add to dashboard Cite

show abstract

“…The clinical pharmacy team performed written and verbal pharmacist interventions with the intervention group, which were accounted for and classified as pharmacist-patient or pharmacist-physician interventions and as resolutive pharmacotherapy problems, preventive pharmacotherapy problems, quality of life, or referral to other medical specialties interventions. The classifications used for pharmacotherapy problems and pharmacist interventions are in accordance with those used in another publication by the authors [ 22 ].…”

Section: Methodsmentioning

confidence: 99%

Cost analysis of pharmaceutical care provided to HIV-infected patients: an ambispective controlled study

et al. 2015

Self Cite

View full text Add to dashboard Cite

BackgroundStudies have shown that pharmaceutical care can result in favorable clinical outcomes in human immunodeficiency virus (HIV)-infected patients, however, few studies have assessed the economic impact. The objective of this study was to evaluate the clinical and economic impact of pharmaceutical care of HIV-infected patients.MethodsA controlled ambispective study was conducted in Brazil from January 2009 to June 2012. Patients were allocated to either intervention or control group. The control group was followed according to standard care while the intervention group was also followed by a pharmacist at each physician appointment for one year. Effectiveness outcomes included CD4+ count, viral load, absence of co-infections and optimal immune response, and economic outcomes included expenses of physician and pharmaceutical appointments, laboratory tests, procedures, and hospitalizations, at six months and one year.ResultsIntervention and control groups included 51 patients each. We observed significant decreases in total pharmacotherapy problems during the study. At six months, the intervention group contained higher percentages of patients without co-infections and of patients with CD4+ >500 cells/mm3. None of the differences between intervention and control group considering clinical outcomes and costs were statistically significant. However, at one year, the intervention group showed higher percentage of better clinical outcomes and generated lower spending (not to procedures). An additional health care system daily investment of US$1.45, 1.09, 2.13, 4.35, 1.09, and 0.87 would be required for each additional outcome of viral load <50 copies/ml, absence of co-infection, CD4+ >200, 350, and 500 cells/mm3, and optimal immune response, respectively.ConclusionThis work demonstrated that pharmaceutical care of HIV-infected patients, for a one-year period, was able to decrease the number of pharmacotherapy problems. However, the clinical outcomes and the costs did not have statistical difference but showed higher percentage of better clinical outcomes and lower costs for some items.

show abstract

“… 2 Partial adherence or non-adherence to ART is one of the main barriers to its effectiveness. 3 , 4 In this context, studies that identify the benefits of different pharmaceutical care practices in supporting adherence to antiretroviral therapy are necessary.…”

Section: Introductionmentioning

confidence: 99%

The Effectiveness of a Pharmaceutical Care Model on Adherence to Antiretroviral Therapy: A SAME-Based Cohort Study in Brazil

Gerenutti¹,

Martinez²,

Bergamaschi³

2017

Adv Pharm Bull

View full text Add to dashboard Cite

Purpose: To verify the effectiveness of a pharmaceutical care model developed by the Specialized Municipal Assistance Service in Sorocaba, Brazil, on adherence to ART among patients infected with HIV.Methods: A cohort study compared adherence to ART in two groups of patients: intervention group (patients assisted with pharmaceutical care, n=130) and non-intervention group (patients attended by the habitual dispensing process, n=229). Antiretroviral adherence was measured by the number of pharmacy refill records in a six-month period. The relationship between the use of other drugs for the treatment of opportunistic infections and the adherence rate in the intervention group and the correlation between adherence and viral load and CD4 lymphocytes were also assessed.Results: Higher adherence rates were observed in the intervention group (p<0.05). The use of others drugs did not influence adherence to ART (p=0.30). There was a positive correlation between adherence and the percentage of patients in the intervention group with undetectable viral loads (p=0.0004) and higher levels of CD4 lymphocytes (p=0.0024).Conclusion: The pharmaceutical care model developed by the SAME improved patient adherence to ART as well as clinical outcomes.

show abstract

Impact of pharmacist interventions on drug-related problems and laboratory markers in outpatients with human immunodeficiency virus infection

Cited by 16 publications

References 36 publications

<p>Drug-Related Problems and Pharmacist Intervention at a General Hospital in the Jazan Region, Saudi Arabia</p>

<p>Drug-Related Problems and Pharmacist Intervention at a General Hospital in the Jazan Region, Saudi Arabia</p>

Cost analysis of pharmaceutical care provided to HIV-infected patients: an ambispective controlled study

The Effectiveness of a Pharmaceutical Care Model on Adherence to Antiretroviral Therapy: A SAME-Based Cohort Study in Brazil

Contact Info

Product

Resources

About